BS: Hypersensitivity Flashcards
Allergic rhinitis, sinusitis (Rx type)
Type I Immediate Hypersensitivity
Allergic rhinitis, sinusitis (manifestation)
Increased mucous secretion, inflammation of upper airways and sinuses
Food Allergies (Rx type)
Type I Immediate Hypersensitivity
Food Allergies (manifestation)
Increased peristalsis due to contraction of intestinal muscles
Bronchial Asthma (Rx type)
Type I Immediate Hypersensitivity
Bronchial Asthma (manifestation)
Airway Obstruction caused by bronchial smooth muscle hyperactivity, inflammation and tissue injury in late phase
Anaphylaxis (Rx type)
Type I Immediate Hypersensitivity
Anaphylaxis (manifestation)
Hypotension caused by vasodilation, airway obstruction due to bronchoconstriction and laryngeal edema
Autoimmune hemolytic anemia (Rx type)
Type II: Antibody-mediated hypersensitivity
Autoimmune hemolytic anemia (target antigen)
erythrocyte membrane proteins (Rh blood group antigens, I antigens)
Autoimmune hemolytic anemia (mechanism)
opsonization and phagocytosis of erythrocytes
Autoimmune hemolytic anemia (manifestation)
Hemolysis, anemia
Autoimmune (idiopathic) thrombocytopenic purpura (Rx type)
Type II: Antibody Mediated Hypersensitivity
Autoimmune (idiopathic) thrombocytopenic purpura (Target antigen)
platelet membrane proteins
Autoimmune (idiopathic) thrombocytopenic purpura (mechanism)
Opsonization and phagocytosis of platelets
Autoimmune (idiopathic) thrombocytopenic purpura (manifestation)
Bleeding
Goodpasture Syndrome (Rx type)
Type II: Antibody Mediated Hypersensitivity
Goodpasture Syndrome (Target antigen)
noncollagenous protein in basement membrane of kidney glomeruli and lung aveoli
Goodpasture Syndrome (mechanism)
Complement and Fc receptor- mediated inflammation
Goodpasture Syndrome (manifestation)
Nephritis, lung hemorrhage
Graves disease “hyperthyroidism” (Rx type)
Type II: Antibody Mediated Hypersensitivity
Graves disease “hyperthyroidism” (target antigen)
Thyroid stimulating hormone (TSH) receptor
Graves disease “hyperthyroidism” (mechanism)
Antibody-mediated stimulation of TSH receptors
Graves disease “hyperthyroidism” (manifestation)
Hyperthyroidism
Myasthenia gravis (Rx type)
Type II: Antibody-mediated hypersensitivity
Myasthenia gravis (target antigen)
acetylcholine receptor
Myasthenia gravis (mechanism)
antibody inhibits acetylcholine binding, down-modulates receptors
Myasthenia gravis (manifestation)
muscle weakness, paralysis
Pemphigus vulgaris (Rx type)
Type II: Antibody-mediated hypersensitivity
Pemphigus vulgaris (target antigen)
proteins in intercellular junctions of epidermal cells
Pemphigus vulgaris (mechanism)
antibody-mediated activation of proteases, disruption of intercellular adhesions
Pemphigus vulgaris (manifestation)
skin vesicles (bullae)
Pernicious anemia (Rx type)
Type II: Antibody-mediated hypersensitivity
Pernicious anemia (target antigen)
intrinsic factor of gastric parietal cells
Pernicious anemia (mechanism)
neutralization of intrinsic factor, decreased absorption of vitamin B12
Pernicious anemia (manifestation)
abnormal erythropoiesis, anemia
Rheumatic fever (Rx type)
Type II: Antibody-mediated hypersensitivity
Rheumatic fever (target antigen)
Streptococcal cell wall antigen; antibody cross-reacts with myocardial antigen
Rheumatic fever (mechanism)
inflammation, macrophage activation
Rheumatic fever (manifestation)
myocarditis, arthritis
Systemic lupus erythematosus (Rx type)
Type III: Immune complex hypersensitivity
Systemic lupus erythematosus (antibody specificity)
DNA, nucleoproteins
Systemic lupus erythematosus (manifestations)
Nephritis, arthritis, vasculitis
Polyarteritis nodosa (Rx type)
Type III: Immune complex hypersensitivity
Polyarteritis nodosa (antibody specificity)
Mostly unknown, sometimes microbial antigens
Polyarteritis nodosa (manifestation)
Vasculitis
Poststreptococcal glomerulonephritis (Rx type)
Type III: Immune Complex Hypersensitvity
Poststreptococcal glomerulonephritis (Antibody specificity)
Streptococcal cell wall antigens
Poststreptococcal glomerulonephritis (manifestation)
Nephritis
Multiple sclerosis (Rx type)
Type IV: T-Cell Mediated Hypersensitivity
Multiple sclerosis (Specificity of pathogenic T cells)
Myelin proteins
Multiple sclerosis (manifestation)
Demyelination in the CNS, sensory and motor dysfunction
Rheumatoid arthritis (Rx type)
Type IV: T-Cell Mediated Hypersensitivity
Rheumatoid arthritis (Specificity of pathogenic T cells)
Unknown antigens in joint
Rheumatoid arthritis (manifestation)
Inflammation of synovium and erosion of cartilage and bone in joints
Type 1 Diabetes (Rx type)
Type IV: T-Cell Mediated Hypersensitivity
Type 1 Diabetes (Specificity of pathogenic T cells)
Pancreatic islet antigens
Type 1 Diabetes (manifestations)
Impaired glucose metabolism, vascular disease
Crohn’s Disease (Rx type)
Type IV: T-Cell Mediated Hypersensitivity
Crohn’s Disease (Specificity of pathogenic T cells)
Unknown, possibly intestinal microbes
Crohn’s Disease (Manifestation)
inflammation of the bowel wall; abdominal pain, diarrhea, hemorrhage
Contact sensitivity (Rx type)
Type IV: T-cell Mediated Hypersensitivity
Contact sensitivity (Specificity of pathogenic T cells)
Modified skin proteins
Contact sensitivity (Manifestation)
DTH reaction in skin, rash
Chronic infections i.e. TB (Rxt type)
Type IV: T-cell Mediated Hypersensitivity
Chronic infections i.e. TB (Specificity of pathogenic T cells)
Microbial proteins
Chronic infections i.e. TB (manifestation)
Chronic inflammation
Viral hepatitis (Rx type)
Type IV: T-cell Mediated Hypersensitivity
Viral hepatitis (Specificity of pathogenic T cells)
virally encoded proteins
Viral hepatitis (manifestation)
CTL-mediated hepatocyte death; liver dysfunction; fibrosis
Super antigen-mediated diseases i.e. toxic shock syndrome
Type IV: T-cell Mediated Hypersensitivity
Superantigen-mediated diseases i.e. toxic shock syndrome (Specificity of pathogenic T cells)
Polyclonal (microbial superantigens activate many T cells of different specificities
Super antigen-mediated diseases i.e. toxic shock syndrome (manifestation)
Fever, shock related to systemic inflammatory cytokine release